Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test
DENVER, Sept. 14, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is sending investors a signal that is impossible to ignore.
The company's CEO, President and director, Amir F. Heshmatpour, just bought another 37,000 shares of NTHI at $3.6654 apiece, putting approximately $136,000 of his own money behind the stock and the timing is what makes this purchase particularly intriguing.
NeOnc had just announced a $15 million registered direct offering at $4.20 per share, meaning Heshmatpour's latest purchase occurred at a substantial discount to the financing price.
That is not the kind of insider transaction small-cap biotech traders casually dismiss.
Heshmatpour has been buying NTHI repeatedly and he isn't the only insider who has been putting money behind the company. In August, Heshmatpour bought additional shares, while founder and Chief Scientific Officer Thomas C. Chen also made substantial purchases.
The Clinical Catalyst
NeOnc reported topline Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma. The company reported a 48.9% six-month progression-free survival rate, versus a pre-specified 20% benchmark.
Even more eye-catching: the company reported a 26.09-month median overall survival.
Five of 24 patients remained on treatment at the data cutoff, including one patient with progression-free survival approaching 19 months and another with an ongoing partial response. For a company operating in one of oncology's toughest areas, those numbers naturally attracted attention, but the real story may be what comes next.
NeOnc says it plans to request a Type B meeting with the FDA to discuss the potential registrational path for NEO100. CEO Heshmatpour said the company's priority is “to engage with the FDA and align on the most efficient path toward a registrational study,” which is a major potential inflection point.
If FDA discussions produce a viable path forward, NEO100 could move from an intriguing clinical-stage asset toward a potentially registrational development program, which makes the insider buying even more interesting, because Heshmatpour is buying after clinical data have been released and while the company is pursuing regulatory discussions.
The Blood-Brain Barrier
There is another piece investors cannot ignore: the blood-brain barrier.
Brain tumors are notoriously difficult to treat because getting drugs into the brain is itself a major challenge. NeOnc's NEO100 program uses intranasal delivery designed to facilitate delivery to the brain through olfactory and trigeminal pathways.
If that approach can translate into meaningful clinical benefit, the opportunity could extend well beyond one small study.
NEO100's Phase 2a study was small, open-label and single-arm. Larger studies are needed. FDA discussions do not guarantee a registrational pathway, or approval.
The company has simultaneously been advancing NEO100 and NEO212, raising capital and moving toward additional clinical and regulatory milestones.
For investors hunting for small-cap biotech names before major catalysts, that's the part of the story that deserves attention, and if NEO100's clinical signal ultimately translates into a successful registrational program, today's insider buying could look considerably more significant in hindsight.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
